Insulet ROA 2007-2018 | PODD

Current and historical return on assets (ROA) values for Insulet (PODD) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Insulet ROA for the three months ending September 30, 2018 was -1.60%.
Insulet ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $-0.01B $0.89B -1.66%
2018-06-30 $-0.02B $0.84B -2.41%
2018-03-31 $-0.02B $0.83B -3.68%
2017-12-31 $-0.03B $0.82B -4.86%
2017-09-30 $-0.03B $0.50B -6.23%
2017-06-30 $-0.03B $0.46B -6.62%
2017-03-31 $-0.03B $0.45B -6.43%
2016-12-31 $-0.03B $0.46B -7.84%
2016-09-30 $-0.05B $0.45B -14.77%
2016-06-30 $-0.06B $0.26B -22.84%
2016-03-31 $-0.07B $0.26B -26.00%
2015-12-31 $-0.07B $0.28B -24.87%
2015-09-30 $-0.05B $0.29B -17.06%
2015-06-30 $-0.04B $0.30B -14.29%
2015-03-31 $-0.06B $0.31B -18.55%
2014-12-31 $-0.05B $0.30B -16.83%
2014-09-30 $-0.05B $0.30B -16.29%
2014-06-30 $-0.06B $0.33B -19.82%
2014-03-31 $-0.04B $0.29B -14.24%
2013-12-31 $-0.05B $0.29B -16.08%
2013-09-30 $-0.05B $0.29B -20.11%
2013-06-30 $-0.04B $0.29B -18.18%
2013-03-31 $-0.05B $0.28B -21.22%
2012-12-31 $-0.05B $0.20B -24.85%
2012-09-30 $-0.06B $0.20B -26.07%
2012-06-30 $-0.06B $0.20B -26.60%
2012-03-31 $-0.05B $0.22B -23.21%
2011-12-31 $-0.05B $0.22B -22.66%
2011-09-30 $-0.05B $0.22B -28.38%
2011-06-30 $-0.05B $0.23B -29.96%
2011-03-31 $-0.06B $0.15B -36.95%
2010-12-31 $-0.06B $0.16B -38.92%
2010-09-30 $-0.06B $0.15B -34.78%
2010-06-30 $-0.06B $0.16B -39.93%
2010-03-31 $-0.07B $0.16B -48.91%
2009-12-31 $-0.07B $0.17B -57.37%
2009-09-30 $-0.09B $0.12B -77.48%
2009-06-30 $-0.09B $0.10B -78.79%
2009-03-31 $-0.10B $0.12B -73.36%
2008-12-31 $-0.10B $0.11B -73.93%
2008-09-30 $-0.08B $0.14B -61.08%
2008-06-30 $-0.07B $0.16B -55.02%
2008-03-31 $-0.06B $0.12B -47.37%
2007-12-31 $-0.06B $0.13B -47.41%
2007-09-30 $-0.05B $0.14B -51.28%
2007-06-30 $-0.05B $0.15B -70.87%
2007-03-31 $-0.04B $0.05B -156.19%
2006-12-31 $-0.04B $0.06B -252.63%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $4.838B $0.464B
INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $126.543B 19.40
Abbott Laboratories (ABT) United States $126.526B 25.64
Stryker (SYK) United States $64.420B 24.28
Boston Scientific (BSX) United States $51.491B 26.02
Baxter (BAX) United States $35.393B 22.86
Zimmer Biomet Holdings (ZBH) United States $23.875B 15.48
Smith & Nephew SNATS (SNN) United Kingdom $16.038B 0.00
ResMed (RMD) United States $14.846B 28.31
Perrigo (PRGO) Ireland $8.596B 13.05
Bio-Rad Laboratories (BIO) United States $8.274B 52.91
Canopy Growth (CGC) Canada $8.174B 0.00
Hill-Rom Holdings (HRC) United States $6.270B 19.88
Aurora Cannabis (ACB) Canada $6.172B 33.68
Haemonetics (HAE) United States $5.727B 50.36
ICU Medical (ICUI) United States $4.968B 27.68
Agios Pharmaceuticals (AGIO) United States $4.052B 0.00
Hutchison China MediTech (HCM) China $4.010B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.990B 0.00
Neogen (NEOG) United States $3.294B 49.88
NuVasive (NUVA) United States $3.166B 29.46
National Vision Holdings (EYE) United States $3.024B 58.49
Quidel (QDEL) United States $2.507B 32.68
Aphria (APHA) $2.433B 0.00
NxStage Medical (NXTM) United States $1.933B 0.00
Phibro Animal Health (PAHC) United States $1.409B 19.95
AtriCure (ATRC) United States $1.241B 0.00
Cardiovascular Systems (CSII) United States $1.058B 1524.50
VAREX IMAGING (VREX) United States $0.999B 20.07
Meridian Bioscience (VIVO) United States $0.823B 26.23
Surmodics (SRDX) United States $0.794B 121.41
OraSure Technologies (OSUR) United States $0.772B 43.48
Eagle Pharmaceuticals (EGRX) United States $0.756B 24.24
MacroGenics (MGNX) United States $0.740B 0.00
Cerus (CERS) United States $0.716B 0.00
PetIQ (PETQ) United States $0.705B 20.03
Lantheus Holdings (LNTH) United States $0.625B 19.34
Omeros (OMER) United States $0.619B 0.00
LeMaitre Vascular (LMAT) United States $0.540B 26.52
Owens & Minor (OMI) United States $0.535B 6.05
Insys Therapeutics (INSY) United States $0.527B 0.00
NanoString Technologies (NSTG) United States $0.521B 0.00
TG Therapeutics (TGTX) United States $0.444B 0.00
Evolus (EOLS) United States $0.403B 0.00
Quanterix (QTRX) United States $0.376B 0.00
Utah Medical Products (UTMD) United States $0.332B 21.45
Cytosorbents (CTSO) United States $0.313B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.264B 0.00
Surface Oncology (SURF) United States $0.225B 0.00
Rockwell Medical (RMTI) United States $0.214B 0.00
BioLife Solutions (BLFS) United States $0.204B 275.00
Chimerix (CMRX) United States $0.172B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.146B 0.00
Fonar (FONR) United States $0.141B 7.06
Imprimis Pharmaceuticals (IMMY) United States $0.123B 0.00
Chembio Diagnostics (CEMI) United States $0.106B 0.00
United-Guardian (UG) United States $0.080B 16.85
Female Health (VERU) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
Trinity Biotech (TRIB) Ireland $0.066B 21.07
CAS Medical Systems (CASM) United States $0.053B 0.00
Neurotrope (NTRP) United States $0.048B 0.00
ImmuCell (ICCC) United States $0.043B 0.00
Capricor Therapeutics (CAPR) United States $0.029B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.018B 0.00
Senestech (SNES) United States $0.017B 0.00
Akers Biosciences Inc (AKER) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00